Compare Enveric Biosciences Inc (ENVB) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Orion Office REIT Inc — how do they compare? Enveric Biosciences Inc trades at $1.38 (market cap $5.32M), while Orion Office REIT Inc trades at $2.69 (market cap $151.17M). The key difference: Orion Office REIT Inc is far larger — about 28.4× Enveric Biosciences Inc's market cap, and Orion Office REIT Inc pays a 3.01% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | ONL | |
|---|---|---|
Market Cap | $5.32M | $151.17M |
Sector | Health | Real Estate |
52-Week High | $17.40 | $3.04 |
52-Week Low | $1.28 | $1.93 |
Enterprise Value | $408.82K | $634.82M |
Dividend Yield | — | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
ONL trades at $2.66 with no recent price change, reflecting a bearish technical signal. The company reported a net loss of $139.31 million in 2025, with revenue declining to $147.65 million. Despite a high gross margin of 56.71%, negative net income and ROE highlight profitability challenges. Recent news indicates strategic reviews and portfolio repositioning, while analyst consensus is split evenly between Buy and Hold.
The outlook remains cautious due to persistent losses and high debt levels, though asset sales and refinancing efforts provide some stability. Investment opportunities exist if strategic initiatives improve cash flow, but risks include ongoing operational deficits and market volatility in the office REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
